Radiogenomics, the integration of imaging and genomic data, is emerging as a powerful tool for predicting treatment response in hyperthermic oncology. By correlating radiographic biomarkers with tumor-specific genetic profiles, radiogenomics enables precise patient stratification for hyperthermia-based therapies, enhancing therapeutic efficacy while minimizing adverse effects. Advanced imaging modalities, such as MRI and PET, combined with genomic analysis, can identify radiosensitive and thermosensitive tumor subtypes, guiding personalized treatment decisions.
As hyperthermia gains traction as an adjunct to radiotherapy and chemotherapy, radiogenomics offers a non-invasive, predictive approach to optimizing patient outcomes. To gain detailed insights into “Radiogenomics as a Predictor of Response in Hyperthermic Oncology,” join eminent Radiation Oncologist Dr. Nagraj Huilgol in our…
